U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07610369) titled 'The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease' on May 15.
Brief Summary: The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Depression
Parkinson's Disease (PD)
Intervention:
DRUG: Psilocybin (drug)
Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring
DRUG: Psilocybin (drug)
Single dose of psilocybin ranging from low ("microdose") to high delivered orally wit...